Harvard Bioscience (FRA:HBI0) Construction In Progress: €0.00 Mil (As of Mar. 2026)


FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
48 GF Score
Price €4.08
GF Value €13.30
! 6 Warning Signs
View Full Analysis

What is Harvard Bioscience Construction In Progress?

Harvard Bioscience FRA:HBI0 48 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 48/100 and a GF Value™ of €13.30. The stock has 6 warning signs investors should review.

Harvard Bioscience Construction In Progress Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Construction In Progress Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Harvard Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:HBI0
48GF Score
Harvard Bioscience Inc FRA:HBI0
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Harvard Bioscience (FRA:HBI0) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Harvard Bioscience and its competitors.
Is Harvard Bioscience's Construction In Progress too high?
Harvard Bioscience's current Construction In Progress is €0.00 Mil. Overall, Harvard Bioscience has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Construction In Progress compare to FEMY and RVP?
Harvard Bioscience's Construction In Progress of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Construction In Progress of €0.00 Mil. The stock's GF Value™ is €13.30, compared to a current price of €4.08 — trading 69.3% below its estimated fair value. The current Construction In Progress is €0.00 Mil. Harvard Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.

Key valuation signals for FRA:HBI0:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score

Get the complete analysis for FRA:HBI0

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€13.30
GF Value